Absolute EASI response achieved by lebrikizumab over 16 weeks in patients with moderate-to-severe atopic dermatitis
Por:
Thaçi, D, Puig, L, Papp, K, Gold, LS, Fernández-Peñas, P, Huang, YH, Dossenbach, M, Falques, M, Agell, H, Schönherr, F, Vestergaard, C
Publicada:
1 abr 2025
Resumen:
Filiaciones:
Thaçi, D:
Univ Lubeck, Inst & Comprehens Ctr Inflammatory Med, Lubeck, Germany
Chang Gung Univ, Sch Med, Taoyuan 333, Taiwan
Puig, L:
Univ Autonoma Barcelona, Hosp Santa Creu i St Pau, Barcelona, Spain
Chang Gung Univ, Sch Med, Taoyuan 333, Taiwan
Papp, K:
Univ Toronto, Alliance Clin Res & Prob Med Res, Waterloo, ON, Canada
Chang Gung Univ, Sch Med, Taoyuan 333, Taiwan
Gold, LS:
Henry Ford Hlth Syst, Detroit, MI USA
Chang Gung Univ, Sch Med, Taoyuan 333, Taiwan
Fernández-Peñas, P:
Univ Sydney, Westmead Hosp, Sydney Med Sch, Sydney, NSW, Australia
Chang Gung Univ, Sch Med, Taoyuan 333, Taiwan
Huang, YH:
Chang Gung Univ, Chang Gung Mem Hosp, Linkou Branch, Taoyuan 333, Taiwan
Chang Gung Univ, Sch Med, Taoyuan 333, Taiwan
Dossenbach, M:
Chang Gung Univ, Sch Med, Taoyuan 333, Taiwan
Eli Lilly & Co, Indianapolis, IN USA
Falques, M:
Chang Gung Univ, Sch Med, Taoyuan 333, Taiwan
Almirall SA, Barcelona, Spain
Agell, H:
Chang Gung Univ, Sch Med, Taoyuan 333, Taiwan
Almirall SA, Barcelona, Spain
Schönherr, F:
Chang Gung Univ, Sch Med, Taoyuan 333, Taiwan
Almirall Hermal GmbH, Reinbek, Germany
Vestergaard, C:
Chang Gung Univ, Sch Med, Taoyuan 333, Taiwan
Aarhus Univ Hosp, Aarhus, Denmark
|